Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Shanghai Rightongene Biotechnology Co (SHSE:688217) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Shanghai Rightongene Biotechnology Co EBITDA Margin % Related Terms
Shanghai Rightongene Biotechnology Co EBITDA Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Shanghai Rightongene Biotechnology Co EBITDA Margin % Chart
SHSE:688217 vs VRTX, REGN, RVMD: EBITDA Margin % Comparison
For the Biotechnology subindustry, Shanghai Rightongene Biotechnology Co's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Shanghai Rightongene Biotechnology Co EBITDA Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Shanghai Rightongene Biotechnology Co's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Shanghai Rightongene Biotechnology Co's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Shanghai Rightongene Biotechnology Co (SHSE:688217) has a EBITDA Margin % of -10.35% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Shanghai Rightongene Biotechnology Co and its competitors. According to the industry distribution chart, Shanghai Rightongene Biotechnology Co ranks #415 out of 942 companies in the Biotechnology industry, placing it in the top 44.1%.
Is Shanghai Rightongene Biotechnology Co's EBITDA Margin % too high?
Shanghai Rightongene Biotechnology Co's current EBITDA Margin % is -10.35%. Based on the distribution chart, Shanghai Rightongene Biotechnology Co ranks #415 out of 942 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Shanghai Rightongene Biotechnology Co has a GF Score™ of 62/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Shanghai Rightongene Biotechnology Co's EBITDA Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Shanghai Rightongene Biotechnology Co ranks #415 out of 942 companies for EBITDA Margin %. This puts Shanghai Rightongene Biotechnology Co in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Shanghai Rightongene Biotechnology Co and its competitors. Shanghai Rightongene Biotechnology Co's current EBITDA Margin % is -10.35%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shanghai Rightongene Biotechnology Co stock overvalued right now?
Based on GuruFocus' analysis, Shanghai Rightongene Biotechnology Co (SHSE:688217) is currently considered Significantly Overvalued. The stock's GF Value™ is ¥15.00, compared to a current price of ¥24.70 — trading 64.7% above its estimated fair value. The current EBITDA Margin % is -10.35%. Shanghai Rightongene Biotechnology Co's overall GF Score™ is 62/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Shanghai Rightongene Biotechnology Co (SHSE:688217), the current EBITDA Margin % is -10.35% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Shanghai Rightongene Biotechnology Co (SHSE:688217) Overvalued in 2026?
Based on GuruFocus' analysis, Shanghai Rightongene Biotechnology Co stock appears to be overvalued.
The current stock price of ¥24.70 is trading 64.7% above its estimated GF Value™ of ¥15.00.
GuruFocus considers Shanghai Rightongene Biotechnology Co to be Significantly Overvalued.
Key valuation signals for SHSE:688217:
EBITDA Margin %: -10.35%
GF Value™: ¥15.00 vs. price of ¥24.70 (64.7% above fair value)
No single metric tells the full story. See the SHSE:688217 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Shanghai Rightongene Biotechnology Co Ltd is engaged in the research and development, production, sales, scientific research and testing services of in vitro diagnostic products.
62GF Score
Get the complete analysis for SHSE:688217
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:688217 has been successfully added to your 
